CQS Cayman’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

CQS Cayman’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-7,474	Closed	-$1.09M	–	184
2015 Q3	$1.09M	Buy	+7,474	New	+$1.37M	0.09%	111

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CQS Cayman's BLCM Position: Q4 2015 in Review

CQS Cayman sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2015, closing a stake of 7,474 shares — an estimated $1.09M sold.

CQS Cayman first reported a position in BLCM in Q3 2015 and held it in 1 quarter. The position peaked at $1.09M in Q3 2015. 81 funds tracked by Wall St. Rank hold BLCM as of Q4 2015.

CQS Cayman reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
CQS Cayman sold 7,474 Bellicum Pharmaceuticals, Inc. shares in Q4 2015, an estimated $1.09M.
CQS Cayman first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2015 and held it in 1 quarter.
CQS Cayman's Bellicum Pharmaceuticals, Inc. position peaked at $1.09M in Q3 2015.
81 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2015.

Based on CQS Cayman's 13F filing for Q4 2015, filed 11 Feb 2016.